247 related articles for article (PubMed ID: 21572154)
21. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.
Bongartz T; Sutton AJ; Sweeting MJ; Buchan I; Matteson EL; Montori V
JAMA; 2006 May; 295(19):2275-85. PubMed ID: 16705109
[TBL] [Abstract][Full Text] [Related]
22. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.
Gómez-Reino JJ; Carmona L; Valverde VR; Mola EM; Montero MD;
Arthritis Rheum; 2003 Aug; 48(8):2122-7. PubMed ID: 12905464
[TBL] [Abstract][Full Text] [Related]
23. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists.
Askling J; Fored CM; Brandt L; Baecklund E; Bertilsson L; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; Klareskog L
Ann Rheum Dis; 2005 Oct; 64(10):1421-6. PubMed ID: 15829572
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists.
Isaacs JD
Expert Opin Biol Ther; 2009 Dec; 9(12):1463-75. PubMed ID: 19916731
[TBL] [Abstract][Full Text] [Related]
25. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data.
Askling J; Fahrbach K; Nordstrom B; Ross S; Schmid CH; Symmons D
Pharmacoepidemiol Drug Saf; 2011 Feb; 20(2):119-30. PubMed ID: 21254282
[TBL] [Abstract][Full Text] [Related]
26. Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis.
Ljung L; Simard JF; Jacobsson L; Rantapää-Dahlqvist S; Askling J;
Arthritis Rheum; 2012 Jan; 64(1):42-52. PubMed ID: 21898355
[TBL] [Abstract][Full Text] [Related]
27. [Fully human anti TNF-alpha monoclonal antibodies (adalimumab, golimumab)].
Hirohata S
Nihon Rinsho; 2007 Jul; 65(7):1202-8. PubMed ID: 17642233
[TBL] [Abstract][Full Text] [Related]
28. Safety of biologic therapies--an update.
Keystone EC
J Rheumatol Suppl; 2005 Mar; 74():8-12. PubMed ID: 15742458
[TBL] [Abstract][Full Text] [Related]
29. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists.
Askling J; Fored CM; Baecklund E; Brandt L; Backlin C; Ekbom A; Sundström C; Bertilsson L; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; Klareskog L; Feltelius N
Ann Rheum Dis; 2005 Oct; 64(10):1414-20. PubMed ID: 15843454
[TBL] [Abstract][Full Text] [Related]
30. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
31. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy.
Wolfe F; Michaud K
Am J Med; 2004 Mar; 116(5):305-11. PubMed ID: 14984815
[TBL] [Abstract][Full Text] [Related]
32. Emerging biologic drugs for the treatment of rheumatoid arthritis.
Puppo F; Murdaca G; Ghio M; Indiveri F
Autoimmun Rev; 2005 Nov; 4(8):537-41. PubMed ID: 16214092
[TBL] [Abstract][Full Text] [Related]
33. Rheumatoid arthritis: choice of antirheumatic treatment. Methotrexate first.
Prescrire Int; 2010 Feb; 19(105):30-4. PubMed ID: 20455343
[TBL] [Abstract][Full Text] [Related]
34. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register.
Askling J; Baecklund E; Granath F; Geborek P; Fored M; Backlin C; Bertilsson L; Cöster L; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; van Vollenhoven R; Klareskog L; Feltelius N
Ann Rheum Dis; 2009 May; 68(5):648-53. PubMed ID: 18467516
[TBL] [Abstract][Full Text] [Related]
35. Does safety make a difference in selecting the right TNF antagonist?
Fleischmann R; Yocum D
Arthritis Res Ther; 2004; 6 Suppl 2(Suppl 2):S12-8. PubMed ID: 15228616
[TBL] [Abstract][Full Text] [Related]
36. Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy.
Aaltonen KJ; Joensuu JT; Virkki L; Sokka T; Aronen P; Relas H; Valleala H; Rantalaiho V; Pirilä L; Puolakka K; Uusitalo T; Blom M; Konttinen YT; Nordström D
J Rheumatol; 2015 Mar; 42(3):372-8. PubMed ID: 25593230
[TBL] [Abstract][Full Text] [Related]
37. Malignancy risk of anti-tumor necrosis factor alpha blockers: an overview of systematic reviews and meta-analyses.
Chen Y; Sun J; Yang Y; Huang Y; Liu G
Clin Rheumatol; 2016 Jan; 35(1):1-18. PubMed ID: 26573205
[TBL] [Abstract][Full Text] [Related]
38. [Risk of infection through use of selective immunomodulating drugs for rheumatoid arthritis].
Harboe E; Damås JK; Omdal R; Frøland SS; Sjursen H
Tidsskr Nor Laegeforen; 2012 Sep; 132(16):1867-71. PubMed ID: 22986971
[TBL] [Abstract][Full Text] [Related]
39. Observational studies of infections in rheumatoid arthritis: a metaanalysis of tumor necrosis factor antagonists.
Bernatsky S; Habel Y; Rahme E
J Rheumatol; 2010 May; 37(5):928-31. PubMed ID: 20360181
[TBL] [Abstract][Full Text] [Related]
40. The Risk of Tuberculosis in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor-α Antagonist: A Metaanalysis of Both Randomized Controlled Trials and Registry/Cohort Studies.
Ai JW; Zhang S; Ruan QL; Yu YQ; Zhang BY; Liu QH; Zhang WH
J Rheumatol; 2015 Dec; 42(12):2229-37. PubMed ID: 26472414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]